Literature DB >> 1902434

Cloning and expression in COS-1 cells of a full-length cDNA encoding human coagulation factor X.

T L Messier1, D D Pittman, G L Long, R J Kaufman, W R Church.   

Abstract

A 1.5-kb cDNA (FX) encoding full-length human coagulation factor X was isolated from a human fetal liver cDNA library. The identity of the insert in a selected phage lambda clone was confirmed to be FX by nucleotide (nt) sequence analysis and restriction mapping. This FX cDNA clone contained 1467 bp of coding sequence, no 5'-untranslated sequence, a short 3'-untranslated sequence of 10 nt and a poly(A) tail at the 3'-end. The FX cDNA was inserted into a mammalian expression vector and transfected into COS-1 monkey kidney cells. Media from transfected cells showed evidence of factor X antigen and, following addition of Russel's viper venom factor X activator, enhanced amidolytic activity toward a synthetic peptide rho-nitroanilide substrate. Immunoprecipitation with an anti-factor X monoclonal antibody of [35S]methionine-labeled cell-conditioned media showed evidence of polypeptides of 74, 55, and 17 kDa, as determined by SDS-PAGE followed by autoradiography. Together, these results indicate that an active factor X can be successfully expressed in a recombinant DNA expression system. This approach will allow the systematic structure/function investigation of this important blood-clotting enzyme.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1902434     DOI: 10.1016/0378-1119(91)90141-w

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  7 in total

1.  Production of a self-activating CBM-factor X fusion protein in a stable transformed Sf9 insect cell line using high cell density perfusion culture.

Authors:  Volker M Gorenflo; Tom A Pfeifer; Gary Lesnicki; Emily M Kwan; Thomas A Grigliatti; Douglas G Kilburn; James M Piret
Journal:  Cytotechnology       Date:  2004-03       Impact factor: 2.058

2.  Processing and trafficking of clotting factor X in the secretory pathway. Effects of warfarin.

Authors:  C Stanton; R Wallin
Journal:  Biochem J       Date:  1992-05-15       Impact factor: 3.857

3.  Generation of hyperfunctional recombinant human factor IX variants expressed in human cell line SK-Hep-1.

Authors:  Aline Sousa Bomfim; Marcela Cristina Corrêa de Freitas; Virgínia Picanço Castro; Mario Abreu Soares Neto; Ricardo Pádua; Dimas Tadeu Covas; Elisa Maria Sousa Russo
Journal:  Biotechnol Lett       Date:  2020-11-01       Impact factor: 2.461

4.  One missense mutation in the factor X gene causing factor X deficiency--factor X Kanazawa.

Authors:  E Morishita; K Yamaguchi; H Asakura; M Saito; M Yamazaki; Y Ontachi; T Mizutani; M Kato; S Nakao
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

5.  Recombinant Expression of Complex Proteins in Human Cell Lines.

Authors:  Aline de Sousa Bomfim; Bruna Samhan Archangelo; Aline Sanches Pereira; Elisa Maria de Sousa Russo
Journal:  Methods Mol Biol       Date:  2022

Review 6.  Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics.

Authors:  Rodney M Camire
Journal:  J Thromb Thrombolysis       Date:  2021-04-22       Impact factor: 5.221

7.  Functional characterization of a chimeric soluble Fas ligand polymer with in vivo anti-tumor activity.

Authors:  Sophie Daburon; Christel Devaud; Pierre Costet; Aurore Morello; Laure Garrigue-Antar; Mike Maillasson; Nathalie Hargous; Delphine Lapaillerie; Marc Bonneu; Julie Dechanet-Merville; Patrick Legembre; Myriam Capone; Jean-François Moreau; Jean-Luc Taupin
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.